CD8A and neoplasm: For example, the CXCL9/CXCL10–CXCR3 axis has been shown to facilitate directional migration of effector CD8+ T cells toward tumor cores, promoting effective immune surveillance and enhancing responses to checkpoint blockade therapies (37, 38).